drugset / Trial / NCT06692465
To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
Phase 2
Completed
180 enrolled
Suzhou Kintor Pharmaceutical Inc
Suzhou Koshine Biomedica, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of GT20029 solution.
Timeline
- Start
- 2023-04-13
- Primary completion
- 2023-12-14
- Completion
- 2024-06-30
Outcome
Met primary endpoint
release “2024年4月21日，公司自主研发的AR-PROTAC化合物GT20029酊外用治疗男性雄激素性脱发的中国II期临床试验达到主要研究终点。” kintor.com.cn ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT20029 | Unknown | 5 mg | — |
| Subject | GT20029 | Unknown | 10 mg | — |